FindTrial
Sign In

Effect of penetration enhancers in topical photodynamic therapy

Comparison of 20% Aminolaevulinic acid (ALA) versus 20% ALA 2% dimethyl sulphoxide (DMSO) 2% ethylene diamine tetraacetic acid (EDTA) in topical photodynamic therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN92678315
Enrollment
Unknown
Registered
2003-09-12
Start date
2002-04-08
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin and Connective Tissue Diseases: Topical photodynamic therapy (PDT) Signs and Symptoms Topical photodynamic therapy (PDT)

Interventions

Two treatment arms in the study, randomised in double blind fashion to receive either topical 20% ALA or 20% ALA, 2% EDTA cream. Both groups will then receive light treatment to the areas to which the

Sponsors

Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients referred for PDT as judged appropriate by dermatologists in local area 2. Patients will have basal cell carcinomas, Bowen's disease or actinic keratoses and will be randomised depending on diagnosis

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Response of skin lesion clinically by size change at 3 month follow ups.—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026